Anthrax

BIODEFENSE: Research Methodology and Animal Models

Volumn , Issue , 2005, Pages 77-93

  Leffel, Elizabeth K ^a   Pitt, Louise M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888661589     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420038118-10     Document Type: Chapter

References (94)

1. Albrink, W.S., Pathogenesis of inhalation anthrax, Bacteriol. Rev., 25, 268, 1961.
2. Brachman, P.S., Inhalation anthrax, Ann. N Y Acad. Sci., 353, 83, 1980.
3. Laforce, F.M., Woolsorters’ disease in England, Bull. N Y Acad. Med., 54, 956, 1978.
4. Hambleton, P., Carman, J.A., and Melling, J., Anthrax: the disease in relation to vaccines, Vaccine, 2, 125, 1984.
5. Jager, H.G., Booker, H.H., and Hubschle, O.J., Anthrax in cheetahs (Acinonyx jubatus) in Namibia, J. Wildl. Dis., 26, 423, 1990.
6. Friedlander, A.M., Anthrax: clinical features, pathogenesis, and potential biological warfare threat, Curr. Clin. Top. Infect. Dis., 20, 335, 2000.
7. Hail, A.S., et al. Comparison of noninvasive sampling sites for early detection of Bacillus anthracis spores from rhesus monkeys after aerosol exposure, Mil. Med., 164, 833, 1999.
8. Little, S.F. and Ivins, B.E., Molecular pathogenesis of Bacillus anthracis infection, Microbes Infect., 1, 131, 1999.
9. Friedlander, A.M., Anthrax. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Office of Surgeon General at TMM Publications, Washington, DC, 1997, 467.
10. Zilinskas, R.A., Iraq’s biological weapons. The past as future? JAMA, 278, 418, 1997.
11. Jernigan, D.B., et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis., 8, 1019, 2002.
12. Hagan, B., Hagan and Bruner’s Microbiology and Infectious Diseases of Domestic Animals, 8th ed., Cornell University Press, Ithaca, NY, 1988, 206.
13. Ivins, B.E., et al. Immunization studies with attenuated strains of Bacillus anthracis, Infect. Immun., 52 454, 1986.
14. Abalakin, V.A. and Cherkasskii, B.L., Use of inbred mice as a model for the indication and differentiation of Bacillus anthracis strains, Zh. Mikrobiol. Epidemiol. Immunobiol., 2, 146, 1978.
15. Welkos, S.L., Keener, T.J., and Gibbs, P.H., Differences in susceptibility of inbred mice to Bacillus anthracis, Infect. Immun., 51, 795, 1986.
16. Shibaya, M., Kubomichi, M., and Watanabe, T., The genetic basis of host resistance to Bacillus anthracis in inbred mice, Vet. Microbiol., 26, 309, 1991.
17. Welkos, S.L. and Friedlander, A.M., Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis, Microb. Pathog., 4, 53, 1988.
18. Welkos, S.L., Vietri, N.J., and Gibbs, P.H., Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: Role of plasmid pX02 and chromosome in strain-dependent virulence, Microb. Pathog., 14, 381, 1993.
19. Lyons, C.R., et al. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility, Infect. Immun., 72, 4801, 2004.
20. Flick-Smith, H.C., et al. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain, Microb. Pathog., 38, 33, 2005.
21. Chabot, D.J., et al. Anthrax capsule vaccine protects against experimental infection, Vaccine, 23, 43, 2004.
22. Drysdale, M., et al. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax, Embo. J., 24, 221, 2005.
23. Pickering, A.K., et al. Cytokine response to infection with Bacillus anthracis spores, Infect. Immun., 72, 6382, 2004.
24. Steward, J., Lever, et al. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones, J. Antimicrob. Chemother., 54, 95, 2004.
25. Lincoln, R.E., et al. Advances in Veterinary Science, Academic Press, New York, 1964, 327.
26. Jones, W.I., Jr., et al. In vivo growth and distribution of anthrax bacilli in resistant, susceptible, and immunized hosts, J. Bacteriol., 94, 600, 1967.
27. Behring, E. and Nissen, F., Ueber bakterienfeindliche, Eigenschaften verschiedener Blutserumarten, Z. F. Hyg., 8, 412, 1890.
28. Hachisuka, Y., Germination of B. anthracis spores in the peritoneal cavity of rats and establishment of anthrax, Jpn. J. Microbiol., 13, 199, 1969.
29. Beall, F.A., Taylor, M.J., and Thorne, C.B., Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis, J. Bacteriol., 83, 1274, 1962.
30. Beall, F.A. and Dalldorf, F.G., The pathogenesis of the lethal effect of anthrax toxin in the rat, J. Infect. Dis., 116, 377, 1966.
31. Haines, B.W., Klein, F., and Lincoln, R.E., Quantitative assay for crude anthrax toxins, J. Bacteriol., 89, 74, 1965.
32. Lincoln, R.E., et al. Value of field data for extrapolation in anthrax, Fed. Proc., 26, 1558, 1967.
33. Fish, D.C., et al. Pathophysiological changes in the rat associated with anthrax toxin, J. Infect. Dis., 118, 114, 1968.
34. Walker, J.S., et al. Temperature response in animals infected with Bacillus anthracis, J. Bacteriol., 94, 552, 1967.
35. Bonventre, P.F., et al. Attempts to implicate the central nervous system as a primary site of action for Bacillus anthracis lethal toxin, Fed. Proc., 26, 1549, 1967.
36. Ivins, B.E., Ristroph, J.D., and Nelson, G.O., Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin, Appl. Environ. Microbiol., 55, 2098, 1989.
37. Mourez, M., et al. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis, Proc. Natl. Acad. Sci. USA, 100, 13803, 2003.
38. Sarac, M.S., et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo, Infect. Immun., 72, 602, 2004.
39. Sawada-Hirai, R., et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed, J. Immune Based Ther. Vaccines, 2, 5, 2004.
40. Webster, J.I., Moayeri, M., and Sternberg, E.M., Novel repression of the glucocorticoid receptor by anthrax lethal toxin, Ann. N Y Acad. Sci., 1024, 9, 2004.
41. Turnbull, P.C., et al. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity, Infect. Immun., 52, 356, 1986.
42. Ivins, B.E., et al. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants, Infect. Immun., 60, 662, 1992.
43. Ivins, B.E. and Welkos, S.L., Recent advances in the development of an improved, human anthrax vaccine, Eur. J. Epidemiol., 4, 12, 1988.
44. Ivins, B.E., et al. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen, Infect. Immun., 58, 303, 1990.
45. Little, S.F. and Knudson, G.B., Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig, Infect. Immun., 52, 509, 1986.
46. Ross, J., On the histopathology of experimental anthrax in the guinea pig, Br. J. Exp. Pathol., 36, 336, 1955.
47. Ross, J., The pathogenesis of anthrax following the administration of spores by the respiratory route, J. Path. Bacteriol., 73, 485, 1957.
48. Puziss, M. and Wright, G.G., Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man, J. Bacteriol., 85, 230, 1963.
49. Benjamin, E., et al. In LD50 of Aerosolized B. anthracis and Deposition of Spores in the Hartley Guinea Pig, American Society for Microbiology Biodefense Research Meeting, Baltimore, MD, abstract 96(R), 2005.
50. Ivins, B., et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs, Vaccine, 13, 1779, 1995.
51. Altboum, Z., et al. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs, Infect. Immun., 70, 6231, 2002.
52. Little, S.F., et al. Development of an in vitro -based potency assay for anthrax vaccine, Vaccine, 22, 2843, 2004.
53. Kobiler, D., et al. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization, Infect. Immun., 70, 544, 2002.
54. Barnes, J.M., The development of anthrax following the administration of spore by inhalation, Br. J. Exp. Pathol., 28, 385, 1947.
55. Dalldorf, F.G. and Beall, F.A., Capillary thrombosis as a cause of death in experimental anthrax, Arch. Pathol., 83, (2), 154-61, 1967.
56. Fasanella, A., et al. Detection of anthrax vaccine virulence factors by polymerase chain reaction, Vaccine, 19, 4214, 2001.
57. Kolesnik, V.S., et al. Experimental anthrax infection in laboratory animals with differing species susceptibility to the causative agent, Zh. Mikrobiol. Epidemiol. Immunobiol., 6, 3, 1990.
58. Terril, L. and Clemons, D., The Laboratory Guinea Pig, CRC Press, Boca Raton, FL, 1998, p. 2-3.
59. Little, S.F., et al. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs, Infect. Immun., 65, 5171, 1997.
60. Reuveny, S., et al. Search for correlates of protective immunity conferred by anthrax vaccine, Infect. Immun., 69, 2888, 2001.
61. Hambleton, P. and Turnbull, P.C., Anthrax vaccine development: A continuing story, Adv. Biotechnol. Processes, 13, 105, 1990.
62. Pitt, M.L., et al. In vitro correlate of immunity in an animal model of inhalational anthrax, J. Appl. Microbiol., 87, 304, 1999.
63. Fellows, P.F., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin, Vaccine, 19, 3241, 2001.
64. Zaucha, G.M., et al. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation, Arch. Pathol. Lab. Med., 122, 982, 1998.
65. Ivins, B.E., Fellows, P.F., and Nelson, G.O., Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs, Vaccine, 12, 872, 1994.
66. Pitt, M.L., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax, Vaccine, 19, 4768, 2001.
67. Brachman, P., et al. Evaluation of a human anthrax vaccine, Am. J. Public Health, 52, 632, 1962.
68. Nordberg, B.K., Schmiterlow, C.G., and Hansen, H.J., Pathophysiological investigations into the terminal course of experimental anthrax in the rabbit, Acta. Pathol. Microbiol. Scand., 53, 295, 1961.
69. Klein, F., et al. Pathophysiology of anthrax, J. Infect. Dis., 116, 123, 1966.
70. Lebowich, R.J., McKillip, B.G., and Convoy, J.R., Cutaneous anthraax - A pathologic study with clinical correlation, Am. J. Clin. Pathol., 13, 505, 1943.
71. Little, S.F., Ivins, B.E., Fellows, P.F., Pitt, M.L., Norris, S.L., and Andrews, G.P., Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine, Vaccine, 22, 422, 2004.
72. Fowler, K., McBride, B.W., Turnbull, P.C., and Baillie, L.W., Immune correlates of protection against anthrax, J. Appl. Microbiol., 87, 305, 1999.
73. Borio, L., Frank, D., Mani, V., Chiriboga, C., Pollanen, M., Ripple, M., Ali, S., DiAngelo, C., Lee, J., Arden, J., Titus, J., Fowler, D., O’Toole, T., Masur, H., Bartlett, J., and Inglesby, T., Death due to bioterrorism-related inhalational anthrax: Report of 2 patients, JAMA, 286, 2554, 2001.
74. Grinberg, L.M., Abramova, F.A., Yampolskaya, O.V., Walker, D.H., and Smith, J.H., Quantitative pathology of inhalational anthrax I: Quantitative microscopic findings, Mod. Pathol., 14, 482, 2001.
75. Gleiser, C.A., Pathology of anthrax infection in animal hosts, Fed. Proc., 26, 1518, 1967.
76. Guarner, J., Jernigan, J.A., Shieh, W.J., Tatti, K., Flannagan, L.M., Stephens, D.S., Popovic, T., Ashford, D.A., Perkins, B.A., and Zaki, S. R., Pathology and pathogenesis of bioterrorism-related inhalational anthrax, Am. J. Pathol., 163, 701, 2003.
77. Gill, J. and Melinek, J., Inhalational anthrax, Arch. Pathol. Lab. Med., 126, 993, 2002.
78. Haas, C.N., On the risk of mortality to primates exposed to anthrax spores, Risk Anal., 22, 189, 2002.
79. Albrink, W.S. and Goodlow, R.J., Experimental inhalation anthrax in the chimpanzee, Am. J. Pathol., 35, 1055, 1959.
80. Klein, F., Hodges, D.R., Mahlandt, B.G., Jones, W.I., Haines, B.W., and Lincoln, R.E., Anthrax toxin: causative agent in the death of rhesus monkeys, Science, 138, 1331, 1962.
81. Kelly, D.J., Chulay, J.D., Mikesell, P., and Friedlander, A.M., Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys, J. Infect. Dis., 166, 1184, 1992.
82. Fritz, D.L., Jaax, N.K., Lawrence, W.B., Davis, K.J., Pitt, M.L., Ezzell, J.W., and Friedlander, A.M., Pathology of experimental inhalation anthrax in the rhesus monkey, Lab Invest, 73, 691, 1995.
83. Ivins, B.E., Pitt, M.L., Fellows, P.F., Farchaus, J.W., Benner, G.E., Waag, D.M., Little, S.F., Anderson, G.W., Jr., Gibbs, P.H., and Friedlander, A.M., Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques, Vaccine, 16, 1141, 1998.
84. Kihira, T., Sato, J., and Shibata, T., Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis, J. Infect. Chemother., 10, 97, 2004.
85. Klinman, D. M., Xie, H., Little, S.F., Currie, D., and Ivins, B.E., CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques, Vaccine, 22, 2881, 2004.
86. Vasconcelos, D., Barnewall, R., Babin, M., Hunt, R., Estep, J., Nielsen, C., Carnes, R., and Carney, J., Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis), Lab. Invest., 83, 1201, 2003.
87. Leffel, E., Twenhafel, N., Norris, S.L., and Pitt, L. In Comparison of LD50 of Aerosolized B. anthracis in Rhesus and African Green Monkeys, American Society for Microbiology Biodefense Research Meeting, Baltimore, MD, Abstract 95(R), 2005.
88. Berdjis, C.C., Gleiser, C.A., Hartmen, H.A., Kuehne, R.W., and Gochenour, W.S., Pathogenesis of respiratory anthrax in Macaca mulatta, Br. J. Exp. Pathol., 43, 515, 1962.
89. Gleiser, C.A., Berdjis, C.C., Hartman, H.A., and Gochenour, W.S., Pathology of experimental respiratory anthrax in Macaca mulatta, Br. J. Exp. Pathol., 44, 416, 1963.
90. Kennedy, R.C., Shearer, M.H., and Hildebrand, W., Nonhuman primate models to evaluate vaccine safety and immunogenicity, Vaccine, 15, 903, 1997.
91. Ivins, B.E., Fellows, P.F., Pitt, M.L.M., Estep, J.E., Welkos, S.L., Worsham, P.L., and Friedlander, A.M, Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys, International Workshop of Anthrax, Winchester, UK, 19-21 September, Salisbury Medical Bulletin, 1995, 126.
92. Fellows, P.F., Linscott, M.K., Little, S.F., Gibbs, P., and Ivins, B.E., Anthrax vaccine efficacy in golden Syrian hamsters, Vaccine, 20, 1421, 2002.
93. Patterson, J.L. and Carrion, R., Jr., Demand for nonhuman primate resources in the age of biodefense, Ilar. J., 46, 15, 2005.
94. Abramova, A. and Grinberg, L., Pathological anatomy of anthracic sepsis based on materials from the infectious outbreak of 1979 in Sverdlovsk (some problems of morpho-and pathogenesis), Arkhiv. Patologii., 55, 23, 1993.